Deok Heon Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Deok Heon Lee has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Hanna Jung
Department of Thoracic and Cardiovascular Surgery, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, Korea
5 shared publications - Jae-Ho Lee
Department of Anatomy, School of Medicine, Keimyung University, Daegu 42601, Republic of Korea
5 shared publications Joon Yong Cho
Department of Thoracic and Cardiovascular Surgery, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, Republic of Korea
5 shared publicationsGun-Jik Kim
Department of Thoracic and Cardiovascular Surgery, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, Korea
3 shared publicationsYoung Woo Do
Department of Thoracic and Cardiovascular Surgery, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, Republic of Korea
3 shared publications- Gun-Jik Kim
Department of Thoracic and Cardiovascular Surgery, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, Korea
2 shared publications
Latest Publications
- Open Access
- 28 April 2026
- Published byĀ MDPI AGĀ inĀ Current Issues in Molecular Biology
- Vol.Ā 48 Ā (5) , 456
POU6F1 Expression Predicts Favorable Prognosis in Lung Adenocarcinoma: Validation Using Patient Cohort and TCGA Data
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a leading cause of cancer-related mortality worldwide. Lung adenocarcinoma (AD) and lung squamous cell carcinoma (SCC) represent the two major histological subtypes with distinct molecular characteristics. POU domain class 6 transcription factor 1 (POU6F1) is involved in gene regulation and cellular differentiation, but its clinical significance in NSCLC remains unclear. This study investigated the clinicopathologic and prognostic significance of POU6F1 expression in NSCLC. POU6F1 mRNA expression was analyzed in tumor tissues obtained from 153 patients with NSCLC using quantitative real-time polymerase chain reaction. The associations between POU6F1 expression and clinicopathological characteristics were evaluated, and survival analysis was performed to determine its prognostic value. In addition, publicly available datasets from The Cancer Genome Atlas (TCGA) were analyzed to validate the clinical significance of POU6F1 expression. High POU6F1 expression was observed in 48 patients (31.4%), whereas 105 patients (68.6%) showed low expression. High POU6F1 expression was significantly associated with younger age (p = 0.027), female sex (p = 0.041), non-smoking status (p = 0.002), adenocarcinoma histology (p = 0.021), and the presence of EGFR mutations (p = 0.038). Survival analysis demonstrated that high POU6F1 expression was associated with improved overall survival in patients with NSCLC (p = 0.015). When stratified by histological subtype, higher POU6F1 expression was associated with better survival outcomes in AD but not in SCC. Analysis of TCGA datasets confirmed that elevated POU6F1 expression was significantly associated with favorable survival in AD, whereas no significant prognostic value was observed in SCC. POU6F1 expression is significantly associated with clinicopathological characteristics and improved survival in patients with lung AD. Multivariate Cox regression analysis further confirmed that POU6F1 expression was an independent prognostic factor for overall survival. These findings suggest that POU6F1 may serve as a potential prognostic biomarker based on mRNA expression in NSCLC, particularly in AD. Further studies are warranted to validate these findings at the protein level and to elucidate the underlying biological mechanisms.
- 28 April 2026
- Published byĀ MDPI AGĀ inĀ Current Issues in Molecular Biology
- Vol.Ā 48 Ā (5) , 456
Open AccessPOU6F1 Expression Predicts Favorable Prognosis in Lung Adenocarcinoma: Validation Using Patient Cohort and TCGA Data
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a leading cause of cancer-related mortality worldwide. Lung adenocarcinoma (AD) and lung squamous cell carcinoma (SCC) represent the two major histological subtypes with distinct molecular characteristics. POU domain class 6 transcription factor 1 (POU6F1) is involved in gene regulation and cellular differentiation, but its clinical significance in NSCLC remains unclear. This study investigated the clinicopathologic and prognostic significance of POU6F1 expression in NSCLC. POU6F1 mRNA expression was analyzed in tumor tissues obtained from 153 patients with NSCLC using quantitative real-time polymerase chain reaction. The associations between POU6F1 expression and clinicopathological characteristics were evaluated, and survival analysis was performed to determine its prognostic value. In addition, publicly available datasets from The Cancer Genome Atlas (TCGA) were analyzed to validate the clinical significance of POU6F1 expression. High POU6F1 expression was observed in 48 patients (31.4%), whereas 105 patients (68.6%) showed low expression. High POU6F1 expression was significantly associated with younger age (p = 0.027), female sex (p = 0.041), non-smoking status (p = 0.002), adenocarcinoma histology (p = 0.021), and the presence of EGFR mutations (p = 0.038). Survival analysis demonstrated that high POU6F1 expression was associated with improved overall survival in patients with NSCLC (p = 0.015). When stratified by histological subtype, higher POU6F1 expression was associated with better survival outcomes in AD but not in SCC. Analysis of TCGA datasets confirmed that elevated POU6F1 expression was significantly associated with favorable survival in AD, whereas no significant prognostic value was observed in SCC. POU6F1 expression is significantly associated with clinicopathological characteristics and improved survival in patients with lung AD. Multivariate Cox regression analysis further confirmed that POU6F1 expression was an independent prognostic factor for overall survival. These findings suggest that POU6F1 may serve as a potential prognostic biomarker based on mRNA expression in NSCLC, particularly in AD. Further studies are warranted to validate these findings at the protein level and to elucidate the underlying biological mechanisms.
- Open Access
- 1 June 2024
- Published byĀ Taylor & FrancisĀ inĀ OncoTargets and Therapy
- Vol.Ā ume 17, 463-469
Different Role of TRF1 and TRF2 Expression in Non-Small Cell Lung Cancers
Background: TRF1, TRF2, and TERT (Telomerase reverse transcriptase) are telomere-associated factors that regulate telomere length. Genetic changes in these genes may be associated with cancer pathogenesis; however, this relationship has not yet been comprehensively elucidated in lung cancer. Aim: : Exploring the clinicopathologic and prognostic values of TRF1, TRF2, and TERT mRNA expression in non-small cell lung cancers (NSCLC). Methods: : The clinical significance of TRF1, TRF2, and TERT expression in 141 patients with NSCLC was investigated. Additionally, these findings were supported by the open big data from The Cancer Genome Atlas (TCGA). Results: : TRF1 and TRF2 expression levels tended to be associated with smoking, and TERT expression was positively correlated with age. The survival analysis showed that TRF1 expression predicted a better prognosis for squamous cell carcinoma (SCC), whereas TRF2 expression was associated with a shorter survival in adenocarcinoma. TCGA data also showed a better prognosis for SCC with TRF1 expression. However, the TRF2 results were not in agreement with our data. Conclusions: : We present the clinical and prognostic values of TRF1, TRF2, and TERT expression in NSCLC tissues and TCGA. Our findings suggest that TRF1 expression is a possible prognostic marker for NSCLC, particularly SCC.
- 1 June 2024
- Published byĀ Taylor & FrancisĀ inĀ OncoTargets and Therapy
- Vol.Ā ume 17, 463-469
Open AccessDifferent Role of TRF1 and TRF2 Expression in Non-Small Cell Lung Cancers
Background: TRF1, TRF2, and TERT (Telomerase reverse transcriptase) are telomere-associated factors that regulate telomere length. Genetic changes in these genes may be associated with cancer pathogenesis; however, this relationship has not yet been comprehensively elucidated in lung cancer. Aim: : Exploring the clinicopathologic and prognostic values of TRF1, TRF2, and TERT mRNA expression in non-small cell lung cancers (NSCLC). Methods: : The clinical significance of TRF1, TRF2, and TERT expression in 141 patients with NSCLC was investigated. Additionally, these findings were supported by the open big data from The Cancer Genome Atlas (TCGA). Results: : TRF1 and TRF2 expression levels tended to be associated with smoking, and TERT expression was positively correlated with age. The survival analysis showed that TRF1 expression predicted a better prognosis for squamous cell carcinoma (SCC), whereas TRF2 expression was associated with a shorter survival in adenocarcinoma. TCGA data also showed a better prognosis for SCC with TRF1 expression. However, the TRF2 results were not in agreement with our data. Conclusions: : We present the clinical and prognostic values of TRF1, TRF2, and TERT expression in NSCLC tissues and TCGA. Our findings suggest that TRF1 expression is a possible prognostic marker for NSCLC, particularly SCC.
- Open Access
- 14 August 2023
- Published byĀ Korean Society for Thoracic and Cardiovascular SurgeryĀ inĀ Journal of Chest Surgery
- Vol.Ā 56 Ā (6) , 414-419
Bilateral Cardiac Sympathetic Denervation as a Safe Therapeutic Option for Ventricular Arrhythmias
Soo Jung Park, M.D., Deok Heon Lee, M.D., Ph.D., Youngok Lee, M.D., Ph.D., Hanna Jung, M.D., Ph.D., Yongkeun Cho, M.D., Ph.D.. J Chest Surg 2023;56:414-9. https://doi.org/10.5090/jcs.23.055
- 14 August 2023
- Published byĀ Korean Society for Thoracic and Cardiovascular SurgeryĀ inĀ Journal of Chest Surgery
- Vol.Ā 56 Ā (6) , 414-419
Open AccessBilateral Cardiac Sympathetic Denervation as a Safe Therapeutic Option for Ventricular Arrhythmias
Soo Jung Park, M.D., Deok Heon Lee, M.D., Ph.D., Youngok Lee, M.D., Ph.D., Hanna Jung, M.D., Ph.D., Yongkeun Cho, M.D., Ph.D.. J Chest Surg 2023;56:414-9. https://doi.org/10.5090/jcs.23.055
- Open Access
- 31 August 2022
- Published byĀ Korean Society for Thoracic and Cardiovascular SurgeryĀ inĀ Journal of Chest Surgery
- Vol.Ā 55 Ā (6) , 485-488
Surgical Catheterization for Continuous Serratus Anterior Plane Block after Thoracoscopic Lobectomy: A Report of 3 Cases
Soo Jung Park, M.D., Hanna Jung, M.D., Ph.D., Saeyoung Kim, M.D., Ph.D., Deok Heon Lee, M.D., Ph.D.. J Chest Surg -0001;0:. https://doi.org/10.5090/jcs.22.028
- 31 August 2022
- Published byĀ Korean Society for Thoracic and Cardiovascular SurgeryĀ inĀ Journal of Chest Surgery
- Vol.Ā 55 Ā (6) , 485-488
Open AccessSurgical Catheterization for Continuous Serratus Anterior Plane Block after Thoracoscopic Lobectomy: A Report of 3 Cases
Soo Jung Park, M.D., Hanna Jung, M.D., Ph.D., Saeyoung Kim, M.D., Ph.D., Deok Heon Lee, M.D., Ph.D.. J Chest Surg -0001;0:. https://doi.org/10.5090/jcs.22.028
- 10 August 2022
- Published byĀ Georg Thieme Verlag KGĀ inĀ The Thoracic and Cardiovascular Surgeon
- Vol.Ā 70 Ā (05) , 449-450
Reply to Letter to Editor titled āComparing Analgesic Efficacy of Nerve Blocks after Thoracoscopic Surgery: Methodology Is Importantā
Comparing Analgesic Efficacy of Nerve Blocks after Thoracoscopic Surgery: Methodology Is Important We thank the authors for the valuable comments on our paper. It is a great honor to have the opportunity to discuss the methodological aspects of our study. In the following text, we present our point-by-point responses. We hope that our responses will be sufficient to dispel the doubts. First, when the study was planned, the serratus anterior plane block (SAPB) had only just been introduced and implemented at our hospital. SAPB is routinely administered before surgery, whereas the intercostal nerve block (ICNB) is performed by the surgeon at the end of the surgery. Therefore, it was designed in the same way in this paper. We totally agree with your point regarding the preemptive analgesic effect. In another study, currently in progress at our hospital, evaluating the preemptive analgesic effect, locoregional anesthesia was decided to be administered at the same time in the two groups. Second, in this study, we intended to compare only the effects of ICNB and SAPB as much as possible and reduce the bias of other rescue analgesia administration on the analgesic effect. Thus, the numeric rating scale was used just before the administration of rescue analgesia (ketorolac or fentanyl). Therefore, as you stated, the implementation of multimodal analgesic regimens, suggested by enhanced recovery after surgery protocols, was indeed somewhat lacking in the research process. Third, as you suggested, after equalizing 30 mg of ketorolac with 10 mg of morphine, the two groups were compared again. The amount of rescue analgesics was significantly lower in group S than in group I (group I: 28.0 mg ± 13.5 mg, group S: 19.2 mg ± 15.5 mg; p = 0.038). However, no difference in the absolute reduction of 10 mg morphine within 24 hours was observed between the two groups. Furthermore, no difference in minimal clinically important difference (10 mg per 24 hours) was found as you expected. Fourth, we also agree with your opinion. At the time of the study, the quality of recovery 15 questionnaire was not yet widely distributed and used in Korea, including in our hospital. Thus, researchers and patients were not familiar with it. We agree on the need to actively use it in future research. Received: 12 December 2021 Accepted: 08 February 2022 Article published online: 10 August 2022 Ā© 2022. Thieme. All rights reserved. Georg Thieme Verlag KG RüdigerstraĆe 14, 70469 Stuttgart, Germany
- 10 August 2022
- Published byĀ Georg Thieme Verlag KGĀ inĀ The Thoracic and Cardiovascular Surgeon
- Vol.Ā 70 Ā (05) , 449-450
Reply to Letter to Editor titled āComparing Analgesic Efficacy of Nerve Blocks after Thoracoscopic Surgery: Methodology Is Importantā
Comparing Analgesic Efficacy of Nerve Blocks after Thoracoscopic Surgery: Methodology Is Important We thank the authors for the valuable comments on our paper. It is a great honor to have the opportunity to discuss the methodological aspects of our study. In the following text, we present our point-by-point responses. We hope that our responses will be sufficient to dispel the doubts. First, when the study was planned, the serratus anterior plane block (SAPB) had only just been introduced and implemented at our hospital. SAPB is routinely administered before surgery, whereas the intercostal nerve block (ICNB) is performed by the surgeon at the end of the surgery. Therefore, it was designed in the same way in this paper. We totally agree with your point regarding the preemptive analgesic effect. In another study, currently in progress at our hospital, evaluating the preemptive analgesic effect, locoregional anesthesia was decided to be administered at the same time in the two groups. Second, in this study, we intended to compare only the effects of ICNB and SAPB as much as possible and reduce the bias of other rescue analgesia administration on the analgesic effect. Thus, the numeric rating scale was used just before the administration of rescue analgesia (ketorolac or fentanyl). Therefore, as you stated, the implementation of multimodal analgesic regimens, suggested by enhanced recovery after surgery protocols, was indeed somewhat lacking in the research process. Third, as you suggested, after equalizing 30 mg of ketorolac with 10 mg of morphine, the two groups were compared again. The amount of rescue analgesics was significantly lower in group S than in group I (group I: 28.0 mg ± 13.5 mg, group S: 19.2 mg ± 15.5 mg; p = 0.038). However, no difference in the absolute reduction of 10 mg morphine within 24 hours was observed between the two groups. Furthermore, no difference in minimal clinically important difference (10 mg per 24 hours) was found as you expected. Fourth, we also agree with your opinion. At the time of the study, the quality of recovery 15 questionnaire was not yet widely distributed and used in Korea, including in our hospital. Thus, researchers and patients were not familiar with it. We agree on the need to actively use it in future research. Received: 12 December 2021 Accepted: 08 February 2022 Article published online: 10 August 2022 Ā© 2022. Thieme. All rights reserved. Georg Thieme Verlag KG RüdigerstraĆe 14, 70469 Stuttgart, Germany
- Open Access
Prognostic Value of Telomeric Zinc Finger-Associated Protein Expression in Adenocarcinoma and Squamous Cell Carcinoma of Lung
Background and Objectives: Telomeric zinc finger-associated protein (TZAP) is a telomere regulation protein, previously known as ZBTB48. It binds preferentially to elongated telomeres, competing with telomeric repeat factors 1 and 2. TZAP expression may be associated with carcinogenesis, however; this study has not yet been performed in lung cancer. In this study, we examined the clinicopathological and prognostic values of TZAP expression in non-small cell lung cancer (NSCLC). Materials and Methods: Data were collected from The Cancer Genome Atlas. The clinical and prognostic values of TZAP for NSCLC were examined in adenocarcinoma (AD) and squamous cell carcinoma (SCC). Results: TZAP expression significantly increased in NSCLC tissues compared with normal tissues. In AD, TZAP expression was lower in patients with higher T stage (p = 0.005), and was associated with lymph node stage in SCC (p = 0.005). Survival analysis showed shorter disease-free survival in AD patients with lower TZAP expression (p = 0.047). TZAP expression did not have other clinical or prognostic value for AD and SCC. Conclusions: TZAP expression is a potential prognostic marker for NSCLC, especially in patients with AD.
Open AccessPrognostic Value of Telomeric Zinc Finger-Associated Protein Expression in Adenocarcinoma and Squamous Cell Carcinoma of Lung
Background and Objectives: Telomeric zinc finger-associated protein (TZAP) is a telomere regulation protein, previously known as ZBTB48. It binds preferentially to elongated telomeres, competing with telomeric repeat factors 1 and 2. TZAP expression may be associated with carcinogenesis, however; this study has not yet been performed in lung cancer. In this study, we examined the clinicopathological and prognostic values of TZAP expression in non-small cell lung cancer (NSCLC). Materials and Methods: Data were collected from The Cancer Genome Atlas. The clinical and prognostic values of TZAP for NSCLC were examined in adenocarcinoma (AD) and squamous cell carcinoma (SCC). Results: TZAP expression significantly increased in NSCLC tissues compared with normal tissues. In AD, TZAP expression was lower in patients with higher T stage (p = 0.005), and was associated with lymph node stage in SCC (p = 0.005). Survival analysis showed shorter disease-free survival in AD patients with lower TZAP expression (p = 0.047). TZAP expression did not have other clinical or prognostic value for AD and SCC. Conclusions: TZAP expression is a potential prognostic marker for NSCLC, especially in patients with AD.
- Open Access
- 4 December 2020
- Published byĀ Wolters Kluwer HealthĀ inĀ Medicine
- Vol.Ā 99 Ā (49) , e22102
Serratus anterior plane block versus intercostal nerve block for postoperative analgesic effect after video-assisted thoracoscopic lobectomy
Background: Serratus anterior plane block (SAPB) and intercostal nerve block (ICNB) are attractive options for multimodal analgesia in patients undergoing thoracoscopic surgery, but which block is superior remains unclear. Objective: The present study aimed to assess the effect of SAPB versus ICNB on reducing postoperative pain after video-assisted thoracoscopic surgery (VATS) for lobectomy. Methods: This prospective, randomized, active-intervention-controlled, subject-assessor-blinded, single-center, parallel-group trial allocated 18- to 80-year-old patients with American Society of Anesthesiologists status I to III to receive either SAPB or ICNB in a 1:1 ratio. The primary outcome was numerical pain rating scale (NRS) scores during the first 24 hours postoperatively. The secondary outcomes were postoperative cumulative doses of ketorolac and fentanyl, and the occurrence of postoperative adverse effects. Results: Among the 57 patients assessed for eligibility, 50 were randomly assigned in a 1:1 ratio. Due to conversion to open thoracotomy and patient-controlled analgesia pump failure, 4 patients were excluded and 46 were analyzed. The intergroup differences in NRS scores were not statistically significant at any time point. Cumulative consumptions of fentanyl and ketorolac were also not significantly different. No perioperative adverse events occurred. Postoperative complications were also absent, except for nausea (2/23 patients [8.7% in both groups]). Conclusion: Results of the present study do not clarify whether SAPB or ICNB has a superior effect on reducing pain after VATS, thereby suggesting they may exert similar analgesic effects.
- 4 December 2020
- Published byĀ Wolters Kluwer HealthĀ inĀ Medicine
- Vol.Ā 99 Ā (49) , e22102
Open AccessSerratus anterior plane block versus intercostal nerve block for postoperative analgesic effect after video-assisted thoracoscopic lobectomy
Background: Serratus anterior plane block (SAPB) and intercostal nerve block (ICNB) are attractive options for multimodal analgesia in patients undergoing thoracoscopic surgery, but which block is superior remains unclear. Objective: The present study aimed to assess the effect of SAPB versus ICNB on reducing postoperative pain after video-assisted thoracoscopic surgery (VATS) for lobectomy. Methods: This prospective, randomized, active-intervention-controlled, subject-assessor-blinded, single-center, parallel-group trial allocated 18- to 80-year-old patients with American Society of Anesthesiologists status I to III to receive either SAPB or ICNB in a 1:1 ratio. The primary outcome was numerical pain rating scale (NRS) scores during the first 24 hours postoperatively. The secondary outcomes were postoperative cumulative doses of ketorolac and fentanyl, and the occurrence of postoperative adverse effects. Results: Among the 57 patients assessed for eligibility, 50 were randomly assigned in a 1:1 ratio. Due to conversion to open thoracotomy and patient-controlled analgesia pump failure, 4 patients were excluded and 46 were analyzed. The intergroup differences in NRS scores were not statistically significant at any time point. Cumulative consumptions of fentanyl and ketorolac were also not significantly different. No perioperative adverse events occurred. Postoperative complications were also absent, except for nausea (2/23 patients [8.7% in both groups]). Conclusion: Results of the present study do not clarify whether SAPB or ICNB has a superior effect on reducing pain after VATS, thereby suggesting they may exert similar analgesic effects.
- Open Access
Multiple Functions of Fubp1 in Cell Cycle Progression and Cell Survival
The discovery of novel and critical genes implicated in malignant development is a topic of high interest in cancer research. Intriguingly, a group of genes named ādouble-agentā genes were reported to have both oncogenic and tumor-suppressive functions. To date, less than 100 ādouble-agentā genes have been documented. Fubp1 is a master transcriptional regulator of a subset of genes by interacting with a far upstream element (FUSE). Mounting evidence has collectively demonstrated both the oncogenic and tumor suppressive roles of Fubp1 and the debate regarding its roles in tumorigenesis has been around for several years. Therefore, the detailed molecular mechanisms of Fubp1 need to be determined in each context. In the present study, we showed that the Fubp1 protein level was enriched in the S phase and we identified that Fubp1 deficiency altered cell cycle progression, especially in the S phase, by downregulating the mRNA expression levels of Ccna genes encoding cyclin A. Although this Fubp1-cyclin A axis appears to exist in several types of tumors, Fubp1 showed heterogeneous expression patterns among various cancer tissues, suggesting it exhibits multiple and complicated functions in cancer development. In addition, we showed that Fubp1 deficiency confers survival advantages to cells against metabolic stress and anti-cancer drugs, suggesting that Fubp1 may play both positive and negative roles in malignant development.
Open AccessMultiple Functions of Fubp1 in Cell Cycle Progression and Cell Survival
The discovery of novel and critical genes implicated in malignant development is a topic of high interest in cancer research. Intriguingly, a group of genes named ādouble-agentā genes were reported to have both oncogenic and tumor-suppressive functions. To date, less than 100 ādouble-agentā genes have been documented. Fubp1 is a master transcriptional regulator of a subset of genes by interacting with a far upstream element (FUSE). Mounting evidence has collectively demonstrated both the oncogenic and tumor suppressive roles of Fubp1 and the debate regarding its roles in tumorigenesis has been around for several years. Therefore, the detailed molecular mechanisms of Fubp1 need to be determined in each context. In the present study, we showed that the Fubp1 protein level was enriched in the S phase and we identified that Fubp1 deficiency altered cell cycle progression, especially in the S phase, by downregulating the mRNA expression levels of Ccna genes encoding cyclin A. Although this Fubp1-cyclin A axis appears to exist in several types of tumors, Fubp1 showed heterogeneous expression patterns among various cancer tissues, suggesting it exhibits multiple and complicated functions in cancer development. In addition, we showed that Fubp1 deficiency confers survival advantages to cells against metabolic stress and anti-cancer drugs, suggesting that Fubp1 may play both positive and negative roles in malignant development.